ASSESSMENT OF QUALITY OF LIFE IN PATIENTS WITH CHRONIC HEPATITIS C COMBINED WITH NON-ALCOHOLIC FATTY LIVER DISEASE AND OBESITY AFTER COMPREHENSIVE THERAPY

The aim of this study was to assess the effectiveness of combined therapy using ademetionine and ursodeoxycholic acid (UDCA) in patients with chronic hepatitis C (CHC), non-alcoholic fatty liver disease (NAFLD), and obesity. The main objective was to evaluate how this treatment regimen affects clinical indicators, liver function, and overall quality of life, particularly physical and psychological well-being.Materials and methods. A prospective study involved 70 patients with verified CHC diagnosis, NAFLD and obesity. The average age of patients was 58.5 ± 1.5 years. A control group (n = 25, average age 33.2 ± 1.5 years) consisted of healthy individuals.The participants were divided into three groups. The first group received standard antiviral therapy. The second group received antiviral therapy plus ademetionine, and the third group received a combination of ademetionine and UDCA along with antiviral therapy. Quality of life was assessed using SF-36 and EQ-5D questionnaires at the beginning of treatment, and after three and six months of therapy.Results. Patients receiving the combined treatment with ademetionine and UDCA showed the most significant improvements in quality of life, particularly in physical function, pain reduction, and mental health. They reported decreased anxiety and depression and improved social activity. Those receiving antiviral therapy with ademetionine also showed improvement, but to a lesser degree.No significant changes were observed in the control group.Conclusion. Combined therapy with ademetionine and UDCA alongside antiviral treatment is an effective approach for patients with CHC, NAFLD, and obesity, improving both clinical outcomes and quality of life, particularly in physical and psychological domains.